Financials
Financial year 2025
GD Lifescience from Overijse, company number BE0728464654, closed financial year 2025 with a result of € 504,187 after tax. For that financial year GD Lifescience recorded a gross margin of € 706,148 and equity of € 524,259. Compared with financial year 2024, the result moved from € 284,381 to € 504,187. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 24, 2026.
€ 524,259
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 504,187
▲ 77% vs 2024
Profit after tax over the fiscal year.
€ 622,998
▲ 223% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 503,500 paid out
100 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 4,248
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 5,002
▼ 95% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 214,967
▲ 19% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 158,069 | € 147,874 | € 382,695 | € 706,148 | ▲ 85% |
| Profit after taxes | € 122,017 | € 110,939 | € 284,381 | € 504,187 | ▲ 77% |
| Equity | € 393,252 | € 239,191 | € 523,572 | € 524,259 | |
| Total debts | € 41,362 | € 401,900 | € 280,203 | € 410,943 | ▲ 47% |
| Cash | € 194,048 | € 251,230 | € 192,744 | € 622,998 | ▲ 223% |
| Retained profit | € 373,252 | € 219,191 | € 503,572 | € 504,259 | |
| Dividend | € 0 | € 265,000 | € 0 | € 503,500 | |
| Balance sheet total | € 434,614 | € 641,091 | € 803,775 | € 935,202 | ▲ 16% |
Key figures of GD Lifescience, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to GD Lifescience?
What happened at GD Lifescience in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 504,187 (▲ 77% vs 2024). Source: NBB ↗
- New establishment in Overijse. KBO
- Start of the company according to the CBE. KBO
- Isabelle ORLANS became a director. NBB
- Graham Keith DIXON became a director. NBB
In short
From € 122,017 profit in 2022 to € 504,187 profit in 2025.
Paid € 350,418 in corporate taxes since 2022.
Best year ever: 2025, with € 504,187 profit.
Paid out € 768,500 in dividends to the owners in total.
A new publication or filing at GD Lifescience? We notify you, reason included.
Follow GD LifescienceDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind GD Lifescience are Isabelle ORLANS and Graham Keith DIXON. Graham Keith DIXON is also behind ESTETRA.
Directors
According to the 2025 annual accounts
Isabelle ORLANS
Director
since 2019
since 2019
Establishments
Establishment units
Physical locations of this company
Narcissenlaan 8
3090 Overijse
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0728.464.654
- VAT number
- BE 0728.464.654
- Registered office
- Narcissenlaan 8, 3090 Overijse
- Names & denominations
- GD Lifescience
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 13 June 2019
- Peppol
- Active · Active since 13 Jan 2026
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering